The Filing Desk

Kiniksa Pharmaceuticals vs OPKO Health

Kiniksa Pharmaceuticals KNSA · OPKO Health OPK · Pharmaceuticals

Kiniksa Pharmaceuticals reported revenue of $678 million in fiscal 2025, about the same as OPKO Health's $607 million in fiscal 2025. Kiniksa Pharmaceuticals' revenue grew 60.1% in its latest year, and OPKO Health's fell 14.9%. Kiniksa Pharmaceuticals had an operating margin of 11.4%, against -19.4% at OPKO Health. Free cash flow was $136 million at Kiniksa Pharmaceuticals and −$191 million at OPKO Health.

Side by side

Kiniksa PharmaceuticalsOPKO Health
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$678M$607M
Revenue growth60.1%−14.9%
Revenue growth a year, last 5 years—−15.8%
Gross margin88.5%33.9%
Operating margin11.4%−19.4%
Net margin8.7%−37.2%
Free cash flow$136M−$191M
Free cash flow margin20.1%−31.4%
Return on capital—−7.0%
Net debt to EBITDA——
Dividends and buybacks$0M$47M
Change in diluted share count10.6%8.2%
Last close$96.33$1.68
P/E at the last close73.5×—
Insider trades, last 12 monthssold $45.1 million—
Piotroski F-score—4 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Kiniksa PharmaceuticalsOPKO Health
Operating margin
Percent of revenue
Kiniksa PharmaceuticalsOPKO Health
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kiniksa PharmaceuticalsOPKO Health

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kiniksa Pharmaceuticals and OPKO Health pages.